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Digital ischemic loss is a cause of signiﬁcant morbidity in patients with systemic sclerosis (SSc). Microvascular disease with intimal
proliferationandluminalnarrowingofsmalldigitalarteries,aswellasmacrovasculardiseasewithnarrowingorocclusionoflarger
digital arteries, contribute to the perfusion defects involved in digital ischemic loss. Immediate clinical evaluation and treatment
are mandatory at the onset of critical digital ischemia to prevent digital loss. Hospitalization for medical therapies including
intravenous prostacyclin therapy should be considered for all SSc patients who present with critical digital ischemia. Surgical
interventions are typically reserved for patients who fail medical therapies and for those with late stage, necrotic tissue. This paper
summarizes the current knowledge regarding the risk factors, pathogenesis, evaluation, and treatment of digital ischemic loss in
SSc.
1.Introduction
Systemic sclerosis (SSc) is a disease of unknown etiology
characterized by immune activation, tissue ﬁbrosis, and
vasculopathy. Peripheral vascular involvement manifesting
as Raynaud’s phenomenon (RP) aﬀects almost all patients.
In a subset of SSc patients, episodes of progressive digital
ischemia can result in a digital ulcer—a denuded area with
a deﬁned border with loss of epithelialization and loss
of epidermis and dermis. Sustained reduction in digital
perfusion with impaired tissue viability can lead to critical
ischemia, in some cases resulting in gangrene necessitating
amputation. On a microvascular scale, episodes of digi-
tal ischemia are thought to be due to neuroendothelial
imbalance of vasoconstriction and vasodilatation, structural
abnormalities of the vasculature, and intravascular factors
such as platelet activation, procoagulants, and oxidative
stress. Recent studies on macrovascular disease in SSc
suggest that ischemic demarcation and loss of digits occurs
secondary to narrowing or occlusion of larger digital arteries
(vessels of the palmar arch, radial, or ulnar artery) or
medium-sized and large arteries in the lower extremities.
This paper will summarize the current knowledge regarding
the risk factors, pathogenesis, evaluation, and treatment of
digital ischemic loss in SSc.
2. ClinicalBurden
SSc has a prevalence of 1–50 cases per 100,000 people
worldwide [1]. A retrospective review of the clinical status
of 98 patients with SSc, seen between 1985 and 1990, showed
thatamputationof1ormoredigitsduetoischemiaoccurred
in 20.4% of the patients while 9.2% had multiple digit loss
[2]. A more recent review of a prospective cohort from
2001 found that 28 (16%) of 171SSc patients attending a
hospital in the UK had at least one digital amputation and
73 (43%) had experienced at least one episode of severe
digital ischemia as deﬁned by requirement for intravenous
vasodilator therapy, surgical debridement, and/or amputa-
tion [3]. In another larger cohort of 1168SSc patients in the
UK followed over an 18 month period, 17.4% were found
to have complications related to severe digital vasculopathy
including digital ulcers, critical digital ischemia, gangrene,
or the need for digital sympathectomy. One-third of these
patients were on some immunosuppressive treatment, three-
fourths were receiving at least one vasodilator, and one-
ﬁfth were on antiplatelet agents. Sixteen percent had at
least one digital ulcer and 12% required at least one
hospitalization for intravenous prostanoid therapy over the
18 month study period. Furthermore, 1.6% of the total
cohort developed critical digital ischemia, 1.4% developed2 International Journal of Rheumatology
Table 1: Potential risk factors for digital ischemic loss in patients
with systemic sclerosis.
Likely Possible
Diﬀuse cutaneous subtype
Anti-topoisomerase
antibodies
Anti-centromere antibodies
Current smoking
Anti-beta2-glycoprotein I antibodies
Anti-granzyme B antibodies
digital gangrene, 1.1% underwent a sympathectomy, and
0.9% had an amputation during the 18 month period [4].
3. Risk Factors
Predictors of ischemic digital loss in patients with SSc
have been identiﬁed from data collected from observational
studies (Table 1). Patients with long-standing limited cuta-
neous SSc (lcSSc) have traditionally been thought to have
more prominent vascular manifestations than patients with
diﬀuse cutaneous disease (dcSSc) [5]. However, Denton
and colleagues noted that in their analyses of a prospective
cohort of 1168 patients with SSc, severe digital vasculopathy
occurred in 27.5% of the patients with dcSSc versus 13% of
the patients with lcSSc (P<. 0001). There was no correlation
between disease duration and severity of digital vasculopathy
[4].
An initial observation by Herrick et al. found weakly
positive anti-cardiolipin (aCL) antibodies in four of eight
patients with SSc who had severe digital ischemia requiring
amputation [6]. However, a follow-up retrospective analysis
found that there was no diﬀerence in aCL positivity in SSc
patients with severe ischemia (11/31) versus those without
(16/37), or between those who had amputation (5/13) and
those who had not (22/55). Instead, this study found an
association between the presence of the anti-centromere
antibody and severe peripheral ischemia. Seventeen of the
31patients(55%)withsevereischemiawereanti-centromere
antibody positive compared with nine of 37 (24%) without
ischemia (P = .01). There was also a trend for an association
with the presence of the anti-topoisomerase antibody, in
thatsixpatientswithsevereischemiahadanti-topoisomerase
antibodies compared with two patients without ischemia
(P = .08). The authors concluded that complications from
severe digital vasculopathy are more likely in patients with
scleroderma speciﬁc antibodies [7].
Another review of a prospective cohort from the UK also
found that anti-centromere antibody positivity is a predictor
for amputation. Of 171 patients, 75% of whom had lcSSc,
37% were anti-centromere antibody positive and 16.4%
were identiﬁed as having amputations. Of patients who
had undergone amputations, 60.7% were anti-centromere
antibody positive (OR 3.12). Smoking was also found to be
anindependentriskfactorforamputation(OR6.28perpack
per day, 95% CI 1.95 − 20.19) [3].
Other studies have also investigated whether smoking is
a risk factor for poorer outcomes related to digital ischemia.
Previously, Wigley et al. concluded that smoking was not a
risk factor in 98 patients in their SSc cohort at a US tertiary
care center [8]. However, an analysis from a database from
theUKfoundthatintheircohortof101SScpatients,current
smokers were 3-4 times more likely than never-smokers
to incur digital vascular complications. When adjusting
for age, sex, and disease duration, current smokers were
signiﬁcantlymorelikelythannever-smokerstohaverequired
debridement (OR 4.5, 95% CI 1.1–18.3) or admission for
intravenous vasodilators (OR 3.8, 95% CI 1.1–12.9) [9].
A recent study investigated whether anti-beta2-
glycoprotein I (anti-beta2-glycoprotein I antibodies)
and aCL antibodies are correlated with macrovascular
disease, including digital loss in SSc patients. Seventy ﬁve
SSc patients with a history of ischemic digital loss were
matched to 75SSc patients without a history of digital loss.
Anti-beta2-glycoprotein I antibodies was signiﬁcantly more
frequent in SSc patients with digital loss than in patients
without digital loss: 27/75 (36%) in the digital loss group
had these antibodies compared with 14/75 (19%) in the
group without digital loss (P = .017). The IgA subtype
showed the strongest association (OR 4.0, CI 1.1–14.2).
However, there was no diﬀerence in aCL antibody frequency
between the two groups, as has been previously reported.
In addition, after adjusting for demographics, disease type,
smoking status, and anti-centromere antibodies, anti-
beta2-glycoprotein I antibodies positivity was signiﬁcantly
associated with active digital ischemia (OR 9.4, CI 3.5–25.4),
elevated estimated right ventricular systolic pressure (RVSP)
(OR 4.8, CI 1.0–11.4), and increased mortality (OR 2.9,
CI 1.1–7.1). They also noted that patients with a history of
ischemic digital loss have more severe pulmonary vascular
disease with overall a higher RVSP, worse lung severity
scores, and lower diﬀusing capacity of carbon monoxide
(DLco) which might be contributing to the higher mortality.
All in all, anti-beta2-glycoprotein I antibodies is likely
important in scleroderma vascular disease; however, further
research is necessary to determine whether these antibodies
are directly involved in the pathogenesis of disease or
represent an epiphenomenon [10].
In addition, antibodies against novel autoantigens
expressed in the cytotoxic lymphocyte granule pathway have
been associated with the clinical phenotype of ischemic
digital loss in SSc. Speciﬁcally, autoantibodies to granzyme
B, a serine protease found in the cytoplasmic granules of
cytotoxic T cells and natural killer cells, with an important
role in inducing apoptosis and clearance of intracellular
pathogens, has been found to be highly associated with the
phenotype of ischemic digital loss. Investigators at Johns
Hopkins University found that the sera from 16/19 (84.2%)
lcSSc patients with ischemic digital loss immunoblotted for
autoantigenstogranzymeBcomparedwith6/15(40%)lcSSc
patients without ischemic digital loss (OR 8.0, CI 1.6–40.0).
The risk of anti-granzyme B antibodies persisted even when
controlling for the presence of antiphospholipid antibodies
[11]. This in vivo recognition of granzyme B-generated
autoantigen fragments in lcSSc patients with ischemic digital
loss identiﬁes a distinct clinical subset and needs further
investigation.International Journal of Rheumatology 3
4. Pathogenesis
The pathogenesis of SSc is complex and incompletely
understood. The current view of this disease includes the
development of vasculopathy, activation of the cellular and
humoral immune responses, and progressive ﬁbrosis. The
pathological hallmark of SSc is an obliterative vasculopathy
combined with interstitial ﬁbrosis in target organs. Ray-
naud’s phenomenon, a reversible process in primary disease,
is due to dysregulation of the peripheral and autonomic
nervous systems leading to vasospasm. However, in SSc,
ischemia can progress due to irreversible changes within
the endothelium associated with decreased production and
responsiveness of endothelial derived vasodilators (nitric
oxide and prostacyclins) and increased production and
responsiveness of vasoconstrictors (endothelin-1). In addi-
tion, microvessels have increased permeability, increased
leukocyte extravasation, and activation of coagulation and
ﬁbrinolytic factors with platelet aggregation, eventually
leading to thrombosis. This vasculopathy aﬀects capillaries,
arterioles, and even large vessels and progresses to luminal
occlusion due to intimal/medial hypertrophy and adventitial
ﬁbrosis with persistent endothelial damage and apoptosis.
The process of revascularization is also defective in SSc,
aﬀecting both angiogenesis, in which new vessels arise
from preexisting vessels, and vasculogenesis, in which new
vessels derive from endothelial progenitor cells to replace
damaged or senescent blood vessels, despite elevated levels
of angiogenic factors. Therefore, in SSc there is a widespread
obliterative vasculopathy associated with the failure to repair
and replace damaged vessels, thus resulting in poor digital
perfusion and the potential for ischemic digital loss [12].
5. Vascular DiseaseDistribution
Evidence has shown that both proximal and distal arteries
are aﬀected in SSc-related vasculopathy resulting in digital
ischemic loss. Staﬀord et al. evaluated Doppler studies of
arteries in the limbs, neck, and abdomen of 20SSc patients
compared with controls who were non-SSc rheumatology
patients. They found that the ulnar arteries in SSc patients
were signiﬁcantly narrower (P = .002) and smoothly
thickened (P<. 0001) than those of non-SSc controls,
while other arterial beds were not signiﬁcantly diﬀerent [13].
Another retrospective observational study analyzing brachial
angiography found that 12 of 19 patients with SSc who
exhibited Raynaud’s phenomenon and digital ulceration had
ulnar artery occlusion/stenosis with only 2 patients with
radial artery involvement. Ulnar artery involvement was
associated with the dcSSc subtype (P<. 01) [14].
Hasegawa et al. studied macrovascular disease in patients
with SSc with digital ulceration or gangrene using catheter
arteriographyoftheupperand/orlowerextremities.Sevenof
eightpatientsinthisstudywerefoundtohavemacrovascular
occlusion in the upper extremities. Of these, three had
occlusion limited to digital arteries, three had obliteration
of the ulnar and superﬁcial palmar arch, and one had a
radial artery occlusion. Of ﬁve patients who underwent
lower extremity angiography, one had limited digital artery
occlusion, one had occlusion of the posterior tibial artery,
one had dorsalis pedis and arcuate occlusion, and two had
occlusion of the plantar arch [15].
6. ClinicalEvaluation
The initial clinical evaluation for the signs of digital ischemia
includes assessing for persistent discoloration (cyanosis or
pallor), increased pain, digital ulceration, extreme tender-
ness, or frank gangrene. Nailfold capillaroscopic changes
with dilatation, irregularity, megacapillaries, and drop-out
are often present in SSc patients, and progression of these
features may be predictive of the development of digital
ischemia [16]. The diﬀerential diagnoses that should be
considered in all connective tissue disease associated digi-
tal ischemia include proximal occlusive disease, vasculitis,
thromboembolic disease, or severe distal microvascular dis-
ease. As such, all patients should be evaluated for peripheral
pulses, dopplers if pulses are weak or nonpalpable, an Allen’s
test, and possibly ankle-brachial indices. Laboratory analysis
for prothrombotic states including the antiphospholipid
antibodies (lupus anticoagulant, anti-cardiolipin, and anti-
beta2-glycoprotein I antibodies) should be performed in
all patients. Prompt clinical evaluation and referral for
treatment is critical to the prevention of progression to
digital loss [17]; see Figure 1 for an evaluation and treatment
algorithm.
7.Imaging
Angiographic techniques to evaluate for digital occlu-
sions include conventional angiography, magnetic resonance
angiography (MRA) or computed tomography (CT) angiog-
raphy (Table 2). Conventional angiography is extremely
sensitive for identifying stenosis, occlusion, aneurysm, or
other vascular irregularities, but is invasive, involves high
contrast load, and radiation exposure. MRA is noninvasive,
and can visualize the vessel wall in addition to the lumen
and surrounding structures. Spiral CT angiography allows
3-D imaging with shorter scanning times and without
intravenous contrast or ionizing radiation.
The main indication for imaging is to identify proximal
lesions amenable to angioplasty or surgery in cases of
severe digital ischemia. It should be noted that MR and CT
angiography are still investigational techniques and should
be reserved for patients who have contraindications to
conventional angiography. Conventional angiography is still
consideredthe goldstandard to visualizemore distal arteries,
especially if arterial reconstruction is being considered [12].
8. Treatment
Digit-threatening ischemia warrants prompt and aggressive
treatment to control symptoms and prevent digital loss.
As this is considered a medical emergency, hospitalization
should be considered for all patients to expedite inter-
ventions. Nonpharmacologic treatments such as a warm
environment and bed rest to decrease activity or possible4 International Journal of Rheumatology
Angiography
Peripheral pulses
Doppler pulses if non-palpable
Allen’s test
Ankle-brachial index
Appropriate hypercoaguable work-up
Antiphospholipid antibodies
Lupus anticoagulant
Routine evaluation of systemic vasculitis
Persistent cyanosis or pallor
Increased pain
Extremely tender
Digital ulcer
Gangrene
Proximal occlusive disease
Vasculitis
Thromboembolic disease
Severe distal microvascular disease
Warm environment
Best rest
Wound care
Analgesia/sympathetic block
Anti-coagulation∗
Vasodilation
+/− oral agents
∗If no contraindications, and especially if suspect acute thrombosis or embolic disease or hypercoaguable state.
Digital or proximal
sympathectomy
Progressive ischemia
Imaging
Physical examination
Treatment
Laboratory analysis
Symptoms and signs
Diﬀerential diagnosis
IV prostacyclins
Consider surgical
revascularization or
reconstruction
Anti-cardiolipin antibodies
Treat infection with
IV antibiotics
Anti-beta2GPI antibodies
Figure 1: Algorithm for the evaluation and treatment of digital ischemic loss in systemic sclerosis.
injury to the aﬀected limb are essential. A simple xeroform
dressing with an antibiotic ointment canbe used to prevent a
superinfection and allow wound healing. Intravenous antibi-
otics should be used if overlying infection or osteomyelitis is
suspected,especiallyinpatientswhoarebeingconsideredfor
surgical debridement or if there is any collection of purulent
material or necrotic tissue. Surgical debridement is generally
reserved for patients with purulent drainage, necrotic/late
stageischemictissue,orseverestructuralarterialdiseasewho
do not respond to medical therapies.
Analgesia with opioids is of utmost importance as pain
due to critical digital ischemia is extremely intense. Local
anesthetic blocks with lidocaine or bupivicaine without
epinephrine may be helpful for pain control, but these inter-
ventions have not been studied in clinical trials. Temporary
chemical sympathetic block should strongly be considered
for patients with severe pain before surgical sympathectomy
[12].
Anticoagulation is recommended for patients with
rapidly advancing ischemic tissue who do not have con-
traindications. Intravenous heparin for 24–72 hours is
typically used; however, no double-blind clinical trials have
been performed [12]. Theoretically, this approach would be
appropriate in cases where symptoms are suggestive of a new
arterial occlusion thought to be due to an acute thrombosis
or embolization. Further studies are needed to conﬁrm the
eﬃcacy of this approach.
Aggressive vasodilatation is thought to improve blood-
ﬂow to ischemic areas. Firstly, oral calcium channel blocker
doses should be titrated to maximum tolerated doses. How-
ever, intravenous prostacyclins, which not only vasodilate
but also inhibit platelet aggregation, are considered the
mainstay of management for acute digital ischemia. Intra-
venous epoprostenol or iloprost (0.5–2ng/kg/min) daily
infusions for 1–3 days, each infusion lasting 6 hours, is the
recommended regimen. However, for patients with severe
progressive ischemia, continuous prostacyclin infusion and
higher doses may be required as tolerated. Studies have
shown that intravenous iloprost was eﬀective in reducing
both the frequency and severity of ischemic attacks and in
the healing of digital ulcerations [18, 19]. Epoprostenol was
found to decrease the number of new digital ulcers in a
double-blind trialinpatients withSSc-associatedpulmonary
arterial hypertension [20]. Common side eﬀects of these
medicationsincludehypotension,dizziness,headache,ﬂush-
ing, jaw pain, and gastrointestinal symptoms [21].International Journal of Rheumatology 5
Table 2: Radiographic considerations for evaluation of digital ischemic loss in patients with systemic sclerosis.
Modality Pros Cons
Conventional
Angiography
Extremely sensitive for identifying
vascular abnormalities
Invasive
High contrast load
Standardized technique Radiation exposure
Risk of inducing vasospasm
Magnetic Resonance
Angiography (MRA)
Standardized technique
Noninvasive
No contrast load Long scanning time
No radiation exposure Resolution inferior to CT or conventional
angiography in distal digital vessels
Can visualize vessel wall in addition to
lumen
Can visualize surrounding structures
Can visualized venous lesions
Computed
Tomography (CT)
Angiography
Noninvasive Less contrast load than conventional
angiography
Excellent bone and soft tissue spatial
relationships Shorter scanning time
Resolution inferior to conventional
angiograpy in distal digital vessels
If symptoms are persistent and medical therapy fails,
proximal or digital sympathectomy, microsurgical revascu-
larization of the hand, and digital arterial reconstruction
have been reported to improve digital vascular perfusion,
heal digital ulcers, and substantially relieve or eliminate pain
from one to 46 months postoperatively [22].
A proximal sympathectomy involves resection or abla-
tion of a section of the cervical or thoracic sympathetic
chain. This treatment is now only rarely performed due to
its signiﬁcant associated risks such as permanent Horner’s
syndrome,persistentneuralgia,anddecreasedlocalizedcuta-
neous sweating; however, an endoscopic thoracic approach
m a yb es a f e r .S ym p a t h e c t o m yi sl e s se ﬀective in patients with
secondary than primary Raynaud’s phenomenon and the
d u r a t i o na n dd e g r e eo fi m p r o v e m e n ti sv a r i a b l e[ 12].
Digital sympathectomy was introduced in the 1980s as
an alternative to proximal sympathectomy. A recent study in
20 patients primarily with SSc, who had 42 ulcerated digits
due to ischemia, found that periarterial sympathectomy led
to complete healing or decrease in ulcer number in 28 of 42
digits after a mean of 96 months of follow-up. In addition,
therateofamputationinthetreatedpatientswithunderlying
autoimmune disease was half of that for patients with
underlying atherosclerotic disease, indicating that patients
with autoimmune-induced ischemia may be more amenable
to treatment with digital sympathectomy [23]. However,
controlled studies have not yet been performed, and given
that the risk for perioperative complications is reported at
37%, with amputations and recurrent ulcerations at 14%
and 18%, respectively, these procedures should be reserved
for patients with severe ischemia and a threatened digit only
after failure of vasodilator therapy [24]. In addition, these
procedures should be performed by experienced hand or
vascular surgeons at specialty centers.
If there is larger vessel occlusive disease, especially at the
level of the ulnar or radial artery, successful reconstruction
can be performed with vein grafts [13]. Of 15SSc patients
with severe RP and digital ulceration and angiography-
proven ulnar artery occlusion, no patients responded to
conventional medical therapy; however, 8/15 patients under-
went ulnar artery revascularization combined with digital
sympathectomy and all subsequently experienced dramatic
improvement in Raynaud’s phenomenon and healing of
digital ulcers [25].
Ar e c e n tc a s er e p o r td e s c r i b e ss u c c e s s f u lv a s c u l a rr e c o n -
struction, with improved digital temperatures, pain and
cold sensitivity, and health-related outcomes with peripheral
artery bypass for vasoocclusive disease of the superﬁcial
palmer arch and tarsal arch in two SSc patients with severe
digital ischemia [26]. Another case series noted that bypass
surgery was successful in achieving early pain relief and
ischemic wound healing for critical limb ischemia due to
tibial artery occlusion in patients with SSc; however 4/8
of these patients subsequently experienced limb loss and 1
patient developed persistent recurrent ulcers [27]. Further
studies particularly regarding the long-term outcomes of
bypass surgery for the treatment of critical limb ischemia in
SSc are warranted.
9. Conclusion
Systemicsclerosisisacomplexautoimmuneﬁbrosingdisease
with major vascular complications. Digital vasculopathy6 International Journal of Rheumatology
with critical ischemia is one of the more challenging
complications and carries signiﬁcant morbidity in a sub-
stantial proportion of patients. Identiﬁed risk factors for
ischemic digital loss include the diﬀuse subtype of SSc, SSc
speciﬁc antibodies (anti-centromere antibodies and anti-
topoisomerase antibodies), current smoking, anti-beta2-
glycoprotein I antibodies, and anti-granzyme B antibodies.
Ischemic digital loss is related to both macrovascular disease
with involvement of proximal and larger digital arteries,
as well as microvascular involvement caused by neuroen-
dothelial, structural, platelet, and procoagulant eﬀects. The
medical treatment algorithm for critical digital ischemia
includes urgent evaluation for reversible causes, analgesia,
intravenous vasodilator therapies, angiography, and possibly
anticoagulation. Surgical therapies such as sympathectomies
and vascular reconstructions are considered in patients
who fail medical therapy. Further research is necessary
to identify speciﬁc biomarkers for digital ischemia in
patients with SSc, and to develop more eﬀective treat-
ments.
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